Access to ARV Therapy in the Developing World

Partnership to expand access to ARV therapy for patients with HIV/AIDS in resource constrained countries.

BMS Technology Transfer & ARV Licensing

BMS was one of the first companies to state that it would not enforce its patents on antiretrovirals in sub-Saharan Africa. Since 2001, the company has entered into twelve immunity-from-suit agreements for their antiretrovirals Videx® (didanosine) and Zerit® (stavudine). In addition, BMS has entered into two Technology Transfer and Licensing agreements and two Immunity From Suit agreements covering their antiretroviral Reyataz® (atazanavir).

In 2013, Bristol-Myers Squibb entered into an agreement with the Medicines Patent Pool which aims to further access to atazanavir in developing world countries. This agreement includes 110 least developed, low- and middle- income countries where approximately 29 million people are living with HIV. There is no fixed limit on the number of sublicensees, instead, the aim of this agreement is to create a supply of licensed product that can sustainably meet the demands for atazanavir in the territory, including pediatric formulations. A key feature of the agreement is that there are no royalties for countries that were part of the legacy agreements or for sublicensee sales of pediatric formulations in any of the 110 countries included in the Territory.

In 2006, BMS granted a royalty-free license to two generics companies, Aspen (Africa) and Emcure (India), to sell atazanavir in sub-Saharan Africa and India. BMS also transferred technical know-how related to the manufacturing, testing, packaging, storage and handling of the active pharmaceutical ingredient and finished dosage form of atazanavir to these two generic companies. Also in 2006, BMS agreed to allow generic companies seeking approval of generic combination products (including one or more of BMS’ antiretroviral medicines) for developing countries, under the U.S. PEPFAR program, access to confidential regulatory information as long as these companies were operating under appropriate laws and regulations.


  • Bristol-Myers Squibb

    Service Providers
    Staff size: 10,000+

    Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail against serious diseases. Around the...

  • Aspen Pharmacare

    Goods Supplier
    South Africa | Staff size: 5001-10,000

    Aspen Pharmacare Holdings Limited is a multinational South African holding company for pharmaceutical concerns. The Group is committed to sustaining life and promoting healthcare through...

  • Emcure Pharmaceuticals Limited

    Goods Supplier
    India | Staff size: 5001-10,000

    The Company was incorporated as Emcure Pharmaceuticals Private Limited on April 16, 1981 as a private limited company under the Companies Act, 1956.

    They are a growing...

  • Medicines Patent Pool (MPP)

    Goods Supplier, Implementing NGO
    Staff size: 26-50

    The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to HIV, viral hepatitis C and tuberculosis treatments in low- and middle-income...

  • Mylan Laboratories Limited

    Goods Supplier
    United States | Staff size: 10,000+

    Mylan is one of the world’s leading global pharmaceutical companies. Their medicines range from difficult-to-manufacture dosage forms, such as injectables and transdermal patches, to...

  • Ranbaxy Laboratories Limited

    Goods Supplier
    India | Staff size: 10,000+

    Ranbaxy Laboratories Limited (Ranbaxy) is a research based international pharmaceutical company serving customers in over 150 countries. For more than 50 years, we have been providing high...

More Resources

Key Information

LocationEastern Europe, West Africa, Southern Africa, South Asia, North Africa and Middle East, Latin America and Caribbean, Eastern Africa, East Asia and Pacific, Central Asia, Central Africa
  • Start Date 2001